Achema middle east

Canada unveils new labeling initiative to enhance drug safety

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Innovations in Clinical Packaging and Labeling for Global Studies

The sophistication of clinical trial management continues to advance...

Decentralized Clinical Trials: New Demands on Clinical Supply Strategies

The clinical research landscape is experiencing a significant paradigm...

How Automation is Transforming Pharmaceutical Packaging

When it comes to automation technology, the pharmaceutical industry...
- Advertisement -

Canada has rolled out the plain language labeling initiative to improve the safe use of medicines by making drug labels and safety information easier to read and understand for all health care practitioners and Canadians.

Canada health minister Leona Aglukkaq said that millions of Canadians rely on drugs to maintain and improve their health and vague labeling carries some risks.

The government will be making plain language a requirement on drug packages in order to help prevent adverse drug reactions, medication errors and protect Canadian patients, Aglukkaq added.

It was found that one in nine emergency rooms visits were related to drug adverse effects, and 68% of such cases are preventable, but occur due to limited access to products’ information printed on the labels.

Under the new proposal, key safeguards such as a ‘Drug Facts’ table should be imprinted on the label to standardize the format of non-prescription drug labels and assist users to locate important information.

Drug manufactures will have to maintain contact information on labels so that users can report problems and adverse drug reactions, to provide mock-ups of labels and packages for review, and cater evidence.

The new plan will be implemented in phases starting with prescription and followed by non-prescription drugs.

 

Latest stories

Related stories

Innovations in Clinical Packaging and Labeling for Global Studies

The sophistication of clinical trial management continues to advance...

Decentralized Clinical Trials: New Demands on Clinical Supply Strategies

The clinical research landscape is experiencing a significant paradigm...

How Automation is Transforming Pharmaceutical Packaging

When it comes to automation technology, the pharmaceutical industry...

Pharma Packaging Soars to $464B: Growth Factors Revealed

Industry analysts anticipate substantial growth in the global pharmaceutical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »